Vascular Damage and Anti-angiogenic Effects of Tumor Vessel-Targeted Liposomal Chemotherapy

Cancer Research

Volumn 63, Issue 21, 2003, Pages 7400-7409

  Pastorino, Fabio ^a   Brignole, Chiara ^a   Marimpietri, Danilo ^a   Cilli, Michele ^b   Gambini, Claudio ^a   Ribatti, Domenico ^c   Longhi, Renato ^d   Allen, Theresa M ^e   Corti, Angelo ^f   Ponzoni, Mirco ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d CNR   (Italy)

^e UNIVERSITY OF ALBERTA   (Canada)

^f San Raf faele Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 8 ANTIBODY; DOXORUBICIN; EPITOPE; LIPOSOME; NGR PEPTIDE; PEPTIDE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADRENAL TUMOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG TARGETING; DRUG TUMOR LEVEL; ENDOTHELIUM CELL; FEMALE; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOUSE; NEUROBLASTOMA; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL RATE; TARGET CELL DESTRUCTION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD13; DOXORUBICIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; PEPTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 10744233861     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Kolonin, M., Pasqualini, R., and Arap, W. Molecular addresses in blood vessels as targets for therapy. Curr. Opin. Chem. Biol., 5: 308-313, 2001.
2. Trepel, M., Arap, W., and Pasqualini, R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr. Opin. Chem. Biol., 6: 399-404, 2002.
3. Arap, W., Kolonin, M. G., Trepel, M., Lahdenranta, J., Cardo-Vila, M., Giordano, R. J., Mintz, P. J., Ardelt, P. U., Yao, V. J., Vidal, C. I., Chen, L., Flamm. A., Valtanen, H., Weavind, L. M., Hicks, M. E., Pollock, R. E., Botz, G. H., Bucana, C. D., Koivunen, E., Cahill, D., Troncoso, P., Baggerly, K. A., Pentz, R. D., Do, K. A., Logothetis, C. J., and Pasqualini, R. Steps toward mapping the human vasculature by phage display. Nat. Med., 8: 121-127, 2002.
4. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
5. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.
6. Arap, W., Pasqualini, R., and Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (Wash. DC), 279: 377-380, 1998.
7. Curnis, F., Sacchi, A., and Corti, A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Investig., 110: 475-482, 2002.
8. Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., and Li, K. C. Detection of tumor angiogenesis in vivo by αVβ3-targeted magnetic resonance imaging. Nat. Med., 4: 623-626, 1998.
9. Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., and Cheresh, D. A. Tumor regression by targeted gene delivery to the neovasculature. Science (Wash. DC), 296: 2404-2407, 2002.
10. Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B. P., and Reisfeld, R. A. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med., 8: 1369-1375, 2002.
11. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2: 750-763, 2002.
12. Sapra, P., and Allen, T. M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res., 62: 7190-7194, 2002.
13. Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R. A., Shapiro, L. H., Arap, W., and Ruoslahti, E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 60: 722-727, 2000.
14. Curnis, F., Arrigoni, G., Sacchi, A., Fischetti, L., Arap, W., Pasqualini, R., and Corti, A. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res., 62: 867-874, 2002.
15. Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., and Corti, A. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol., 18: 1185-1190, 2000.
16. Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., Bredesen, D. E., and Pasqualini, R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med., 5: 1032-1038, 1999.
17. Bocci, G., Nicolaou, K. C., and Kerbel, R. S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res., 62: 6938-6943, 2002.
18. Miller, K. D., Sweeney, C. J., and Sledge, G. W., Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol., 19: 1195-1206, 2001.
19. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60: 1878-1886, 2000.
20. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., and Kerbel, R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Investig., 105: R15-R24, 2000.
21. Hanahan, D., Bergers, G., and Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Investig., 105: 1045-1047, 2000.
22. Gately, S., and Kerbel, R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J, 7: 427-436, 2001.
23. Maris, J. M., and Matthay, K. K. Molecular biology of neuroblastoma. J. Clin. Oncol., 17: 2264-2279, 1999.
24. Meitar, D., Crawford, S. E., Rademaker, A. W., and Cohn, S. L. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J. Clin. Oncol., 14: 405-414, 1996.
25. Sugiura, Y., Shimada, H., Seeger, R. C., Laug, W. E., and DeClerck, Y. A. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res., 58: 2209-2216, 1998.
26. Ribatti, D., Surico, G., Vacca, A., De Leonardis, F., Lastilla, G., Montaldo, P. G., Rigillo, N., and Ponzoni, M. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci., 68: 1161-1168, 2001.
27. Ribatti, D., Alessandri, G., Vacca, A., Iurlaro, M., and Ponzoni, M. Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. Int. J. Cancer, 77: 449-454, 1998.
28. Pastorino, F., Brignole, C., Marimpietri, D., Sapra, P., Moase, E. H., Allen, T. M., and Ponzoni, M. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res., 63: 86-92, 2003.
29. Colombo, G., Curnis, F., De Mori, G. M., Gasparri, A., Longoni, C., Sacchi, A., Longhi, R., and Corti, A. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J. Biol. Chem., 277: 47891-47897, 2002.
30. Ponzoni, M., Bocca, P., Chiesa, V., Decensi, A., Pistoia, V., Raffaghello, L., Rozzo, C., and Montaldo, P. G. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res., 55: 853-861, 1995.
31. Moreira, J. N., Hansen, C. B., Gaspar, R., and Allen, T. M. A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochim. Biophys. Acta, 1514, 303-317, 2001.
32. Lopez De Mendez, D. E., Kirchmeier, M. J., Gagne, J. F., Pilarski, L. M., and Allen, T. M. Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells. J. Liposome Res., 9: 199-228, 1999.
33. Chambers, A. F., Groom, A. C., and MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer, 2: 563-572, 2002.
34. Engler, S., Thiel, C., Forster, K., David, K., Bredehorst, R., and Juhl, H. A novel metastatic animal model reflecting the clinical appearance of human neuroblastoma: growth arrest of orthotopic tumors by natural, cytotoxic human immunoglobulin M antibodies. Cancer Res., 61: 2968-2973, 2001.
35. Khanna, C., Jaboin, J. J., Drakos, E., Tsokos, M., and Thiele, C. J. Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo, 16: 77-85, 2002.
36. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., and Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res., 54: 987-992, 1994.
37. Jain, R. K. Delivery of molecular medicine to solid tumors. Science (Wash. DC), 271: 1079-1080, 1996.
38. Moase, E. H., Qi, W., Ishida, T., Gabos, Z., Longenecker, B. M., Zimmermann, G. L., Ding, L., Krantz, M., and Allen, T. M. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim. Biophys. Acta, 1510: 43-55, 2001.
39. Zhang, L., Yu, D., Hicklin, D. J., Hannay, J. A., Ellis, L. M., and Pollock, R. E. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res., 62: 2034-2042, 2002.
40. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
41. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
42. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med., 7: 987-989, 2001.
43. Jain, R. K. The next frontier of molecular medicine: delivery of therapeutics. Nat. Med., 4: 655-657, 1998.
44. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., and Thorpe, P. E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science (Wash. DC), 275: 547-550, 1997.
45. Fidler, I. J. Modulation of the organ microenvironment for treatment of cancer metastasis. J. Natl. Cancer Inst. (Bethesda), 87: 1588-1592, 1995.
46. Campbell, R. B., Fukumura, D., Brown, E. B., Mazzola, L. M., Izumi, Y., Jain, R. K., Torchilin, V. P., and Munn, L. L. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res., 62: 6831-6836, 2002.
47. Thurston, G., McLean, J. W., Rizen, M., Baluk, P., Haskell, A., Murphy, T. J., Hanahan, D., and McDonald, D. M. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Investig., 101: 1401-1413, 1998.
48. Muggia, F., and Hamilton, A. Phase III data on Caelyx in ovarian cancer. Eur. J. Cancer, 37 (Suppl. 9): S15-S18, 2001.